Douglas Devine Sells 1,239 Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) Stock – MarketBeat

Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
iRhythm Technologies, Inc. (NASDAQ:IRTC – Get Rating) CFO Douglas Devine sold 1,239 shares of iRhythm Technologies stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $108.90, for a total value of $134,927.10. Following the transaction, the chief financial officer now owns 39,811 shares of the company’s stock, valued at approximately $4,335,417.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
iRhythm Technologies stock traded up $4.38 during mid-day trading on Thursday, reaching $114.66. 9,073 shares of the stock traded hands, compared to its average volume of 405,417. The stock has a market capitalization of $3.42 billion, a PE ratio of -27.24 and a beta of 1.34. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.63 and a quick ratio of 4.43. iRhythm Technologies, Inc. has a 12-month low of $41.66 and a 12-month high of $169.54. The business’s 50-day moving average is $126.14 and its 200-day moving average is $129.01.
iRhythm Technologies (NASDAQ:IRTC – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.26. The company had revenue of $92.40 million during the quarter, compared to analysts’ expectations of $86.76 million. iRhythm Technologies had a negative return on equity of 34.55% and a negative net margin of 36.43%. iRhythm Technologies’s revenue for the quarter was up 24.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.95) earnings per share. Equities analysts anticipate that iRhythm Technologies, Inc. will post -3.26 EPS for the current fiscal year.
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
A number of institutional investors have recently bought and sold shares of IRTC. FNY Investment Advisers LLC purchased a new stake in iRhythm Technologies during the first quarter valued at $55,000. Parallel Advisors LLC grew its holdings in iRhythm Technologies by 380.9% during the fourth quarter. Parallel Advisors LLC now owns 630 shares of the company’s stock valued at $74,000 after purchasing an additional 499 shares during the period. Nisa Investment Advisors LLC grew its holdings in iRhythm Technologies by 211.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,103 shares of the company’s stock valued at $138,000 after purchasing an additional 749 shares during the period. Fieldpoint Private Securities LLC grew its holdings in iRhythm Technologies by 31.3% during the fourth quarter. Fieldpoint Private Securities LLC now owns 1,808 shares of the company’s stock valued at $213,000 after purchasing an additional 431 shares during the period. Finally, First Republic Investment Management Inc. bought a new stake in iRhythm Technologies during the fourth quarter valued at about $216,000. Institutional investors own 97.92% of the company’s stock.
IRTC has been the subject of a number of recent research reports. Wolfe Research initiated coverage on iRhythm Technologies in a research note on Tuesday, April 5th. They set an “underperform” rating and a $105.00 price objective for the company. BTIG Research lowered their price objective on iRhythm Technologies from $180.00 to $155.00 and set a “buy” rating for the company in a research note on Friday, June 24th. StockNews.com began coverage on iRhythm Technologies in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Citigroup cut iRhythm Technologies from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, June 9th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and issued a $135.00 price target (down previously from $183.00) on shares of iRhythm Technologies in a research note on Wednesday, June 22nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $153.67.
iRhythm Technologies Company Profile (Get Rating)
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Further Reading

Insider Buying and Selling by Quarter for iRhythm Technologies (NASDAQ:IRTC)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iRhythm Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and iRhythm Technologies wasn’t on the list.
While iRhythm Technologies currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Today’s interview is a little different, in that you get a LOT of market perspective from someone who’s been analyzing stocks from the ground up, for more than three decades. In this conversation, Kate chats with Nancy Zambell, the chief analyst for the Cabot Money Club Letter – and Nancy has a really deep and varied background in the financial industry – as she mentions in this interview, she’s been a banker, real estate professional, and a stock market analyst.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.

source

Related Articles